Dima Decker
Apellis Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
T-cell and B-cell Immunology, Rheumatoid Arthritis Research and Therapies, Systemic Lupus Erythematosus Research, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Immune Cell Function and Interaction
Most-Cited Works
- → Direct effects of HP Acthar Gel® on human B lymphocyte activation in vitro(2015)38 cited
- → Cross-inhibition between nicotinic acetylcholine receptors and P2X receptors in myenteric neurons and HEK-293 cells(2009)24 cited
- → Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone(2015)24 cited
- → Developing Therapies for C3 Glomerulopathy(2024)15 cited
- → Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept(2020)3 cited
- → #3391 Pegcetacoplan treatment appears to halt disease progression in C3G and primary (idiopathic) IC-MPGN patients: results from the phase 3 VALIANT study(2025)1 cited
- → #288 Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN Patients with or without concomitant immunosuppression in VALIANT(2025)1 cited
- → Immunomodulatory effects of repository corticotropin injection (H.P. Acthar® gel) on the MRL/lpr model of lupus(2016)1 cited
- → Use of Immune Globulin Manufactured from a Blended Plasma Pool of High-Titer RSV and Normal Source Plasma in an Adult with Severe ARDS COVID-19: Case Report(2022)
- → Repository corticotropin injection (H.P. Acthar® Gel) attenuates established collagen-induced arthritis when used alone or as adjuvant therapy with etanercept (Enbrel®) (THER5P.902)(2015)